SUBSCRIBE
SUBSCRIBE
News   Drug Development

Endo Pharmaceuticals Announces Update on Phase III-Program for Orexo AB’s Pain Product Rapinyl(TM)

November 1, 2007 | 
1 min read
STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: On November 1 2007, Orexo´s (STO:ORX) licensing partner Endo Pharmaceuticals has, in connection with the announcement of their Interim Report, left the following information:
Clinical research Phase 3 Europe
MORE ON THIS TOPIC
Close up shot of the dart arrow hit on bulleyes of dartboard to represent that the business reached the target with dark tone picture style. Target and goal as concept.
Diabetes
Lilly Tops Novo in Weight Loss Again, This Time on the Oral Front
February 26, 2026
 · 
2 min read
 · 
Annalee Armstrong
Working man icon pushing the load on the line. Hard work, labor, effort and determination concept.
HIV
Gilead, Merck Clear Path to Market for Daily HIV Pills With New Late-Stage Data
February 26, 2026
 · 
2 min read
 · 
Tristan Manalac
Alarm clock with pause sign, take a break, menopause concept, hormone replacement therapy
Regulatory
Patient Death Forces Partial Freeze on MacroGenics’ Gynecologic Cancer Study
February 25, 2026
 · 
2 min read
 · 
Tristan Manalac
Podcast
Lilly Bests Novo Again, Rare Disease Week Goes Regulatory, More CDC Leadership Upheaval
February 25, 2026
 · 
2 min read
 · 
Heather McKenzie